Holen Sie sich die Stockscreener-App
53.79
4.92%
-2.42
Schlusskurs vom Vortag:
$56.21
Offen:
$57.06
24-Stunden-Volumen:
474.25K
Relative Volume:
0.36
Marktkapitalisierung:
$7.74B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-11.69
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
-9.86%
1M Leistung:
-1.21%
6M Leistung:
+66.14%
1J Leistung:
-26.81%
1-Tages-Spanne:
$53.37
$57.90
1-Wochen-Bereich:
$53.37
$60.45
52-Wochen-Spanne:
$27.66
$76.61
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
53.81 | 8.09B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaxcyte Shares Decline as Capital Research Global Investors Reduces Stake - National Today
Aug PostEarnings: Can Vaxcyte Inc continue delivering strong returnsQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 2,500 Shares - MarketBeat
Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding - Stock Titan
Jefferies Maintains Buy on Vaxcyte (PCVX) March 10, 2026 - Meyka
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity By Investing.com - Investing.com Canada
Jefferies reiterates Vaxcyte stock Buy rating on regulatory clarity - Investing.com UK
Understanding the Setup: (PCVX) and Scalable Risk - Stock Traders Daily
Vaxcyte’s Heavy Equity Raise and Wider Losses Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Neo Ivy Capital Management Has $2.99 Million Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vaxcyte (PCVX) CFO awarded RSUs and options, surrenders shares for taxes - Stock Titan
Vaxcyte (PCVX) CEO receives large RSU and option grants, surrenders shares for tax - Stock Titan
Vaxcyte Earnings Call: Cash Strength, Trials Accelerate - TipRanks
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)? - Yahoo Finance
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. - Yahoo Finance
Vaxcyte, Inc. (PCVX) - DirectorsTalk Interviews
Vaxcyte, Inc. $PCVX Shares Sold by TD Asset Management Inc - MarketBeat
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists - Yahoo Finance
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds - Yahoo Finance
Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New FinancingHas The Bull Case Changed? - simplywall.st
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Volatility - simplywall.st
Analysts’ Top Healthcare Picks: Vaxcyte (PCVX), TransMedics Group (TMDX) - The Globe and Mail
Westfield Capital Management Co. LP Purchases 663,817 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vanguard Group Inc. Has $443.78 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte (PCVX): BTIG Raises Price Target, Maintains Buy Rating | - GuruFocus
JPMorgan Chase & Co. Has $56.37 Million Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans - TipRanks
BTIG raises Vaxcyte price target to $89 on vaccine breadth edge - Investing.com Nigeria
Vaxcyte (NASDAQ:PCVX) Shares Gap Down Following Weak Earnings - MarketBeat
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion By Investing.com - Investing.com Canada
Leerink raises Vaxcyte stock price target on vaccine pipeline expansion - Investing.com Nigeria
Vaxcyte, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... By GuruFocus - Investing.com Canada
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and Strategic Advancements - GuruFocus
Vaxcyte Q4 Earnings Call Highlights - MarketBeat
Vaxcyte (NASDAQ:PCVX) Issues Quarterly Earnings Results - MarketBeat
Vaxcyte Q4 2025 Earnings Call Transcript - MarketBeat
Vaxcyte Launches New $500 Million ATM Equity Program - TipRanks
PCVX: VAX-31 advanced in late-stage trials, with strong financials and manufacturing readiness for 2026 - TradingView
Vaxcyte enters into sales agreement, may sell shares of common stock of up to $500 million - marketscreener.com
Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million - TradingView
Vaxcyte Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vaxcyte Q4 Loss Widens - marketscreener.com
Vaxcyte (NASDAQ: PCVX) launches $500M common stock sales plan - Stock Titan
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Programs Towards Re - GuruFocus
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
All eyes on Vaxcyte earnings as pneumococcal vaccine nears pivotal data - Investing.com Nigeria
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cowan Elvia | SVP, Finance & CAO |
Mar 11 '26 |
Sale |
58.59 |
2,500 |
146,482 |
30,867 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Mar 10 '26 |
Sale |
58.88 |
7,395 |
435,440 |
166,818 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):